Boehringer Ingelheim launches SCOVELLA in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
Ingelheim, Germany, and Bracknell, United Kingdom*SCOVELLA is the first therapy specifically developed and approved for the treatment of hyperinsuli
